Evidence map›Paper›PMID 32443766›Full record

ReviewNutrients2020

Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability.

Anna Mas-Capdevila, Joan Teichenne, Cristina Domenech-Coca, Antoni Caimari, Josep M Del Bas, Xavier Escoté, Anna Crescenti

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06249620 (A Randomized Controlled Trial of Oral Suplementation With AM3, Hesperidin and Spermidine on Immunity Response and Biological Age in Healthy Volunteers.), which is not on this map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06249620 nacompletednot on this mapstarted 2022, after this paper: background citation

A Randomized Controlled Trial of Oral Suplementation With AM3, Hesperidin and Spermidine on Immunity Response and Biological Age in Healthy Volunteers.

TypeinterventionalSponsorIndustrial Farmacéutica Cantabria, S.A.Ran2022 to 2022Enrolled41ConditionsHealthyArmsInmunoferon, Placebo
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. A probioticGut microbes · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Toxicological Assessment ofInternational journal of molecular sciences · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anna Mas-CapdevilaEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Joan TeichenneEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Cristina Domenech-CocaEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Antoni CaimariEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Josep M Del BasEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Xavier EscotéEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Anna CrescentiEurecat, Technology Centre of Catalunya. Nutrition and Health Unit, 43204 Reus, Spain.
Technological Center of Nutrition and Health · ES

Funding

Catalan Government ACCIÓ-EurecatCentre for the Development of Industrial Technology (CDTI) of the Spanish Ministry of Science and Innovation TECNOMIFOOD project (CER-20191010)European Union's Horizon 2020 Research and Innovation Programme Preventomics project-No 818318
6 · The paper itself

Abstract

Recently, hesperidin, a flavonone mainly present in citrus fruits, has emerged as a new potential therapeutic agent able to modulate several cardiovascular diseases (CVDs) risk factors. Animal and in vitro studies demonstrate beneficial effects of hesperidin and its derived compounds on CVD risk factors. Thus, hesperidin has shown glucose-lowering and anti-inflammatory properties in diabetic models, dyslipidemia-, atherosclerosis-, and obesity-preventing effects in CVDs and obese models, and antihypertensive and antioxidant effects in hypertensive models. However, there is still controversy about whether hesperidin could contribute to ameliorate glucose homeostasis, lipid profile, adiposity, and blood pressure in humans, as evidenced by several clinical trials reporting no effects of treatments with this flavanone or with orange juice on these cardiovascular parameters. In this review, we focus on hesperidin's beneficial effects on CVD risk factors, paying special attention to the high interindividual variability in response to hesperidin-based acute and chronic interventions, which can be partly attributed to differences in gut microbiota. Based on the current evidence, we suggest that some of hesperidin's contradictory effects in human trials are partly due to the interindividual hesperidin variability in its bioavailability, which in turn is highly dependent on the α-rhamnosidase activity and gut microbiota composition.

Indexed as

AnimalsAnti-Inflammatory AgentsAtherosclerosisBiological AvailabilityCardiovascular DiseasesCardiovascular SystemCitrusDysbiosisDyslipidemiasFlavanonesGastrointestinal MicrobiomeHesperidinHumansObesityRisk FactorsAnti-Inflammatory AgentsflavanoneFlavanonesHesperidinbioavailabilitycardiovascular diseasesdysbiosisgut microbiotahesperetinhesperidin

Identifiers

PMID32443766
PMCPMC7284956
OpenAlexW3026833994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.